Search hospitals > Michigan > Detroit
Barbara Ann Karmanos Cancer Institute
Claim this profileDetroit, Michigan 48201
Global Leader in Skin Cancer
Global Leader in Lymphoma
Conducts research for Lung Cancer
Conducts research for Uterine Tumors
Conducts research for Cancer
1496 reported clinical trials
101 medical researchers
Summary
Barbara Ann Karmanos Cancer Institute is a medical facility located in Detroit, Michigan. This center is recognized for care of Skin Cancer, Lymphoma, Lung Cancer, Uterine Tumors, Cancer and other specialties. Barbara Ann Karmanos Cancer Institute is involved with conducting 1,496 clinical trials across 847 conditions. There are 101 research doctors associated with this hospital, such as Ammar Sukari, Anthony F. Shields, Hirva Mamdani, MD, and Dipenkumar Modi, M.D..Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Lymphoma
Global LeaderStage IV
Stage III
Stage II
Top PIs
Ammar SukariWayne State University/Karmanos Cancer Institute2 years of reported clinical research
Expert in Skin Cancer
Expert in Squamous Cell Carcinoma
29 reported clinical trials
45 drugs studied
Anthony F. ShieldsBarbara Ann Karmanos Cancer Institute5 years of reported clinical research
Studies Uterine Tumors
Studies Solid Tumors
22 reported clinical trials
65 drugs studied
Hirva Mamdani, MDKarmanos Cancer Institute5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
20 reported clinical trials
29 drugs studied
Dipenkumar Modi, M.D.Karmanos Cancer Institute3 years of reported clinical research
Expert in Lymphoma
Studies Diffuse Large B-Cell Lymphoma
22 reported clinical trials
48 drugs studied
Clinical Trials running at Barbara Ann Karmanos Cancer Institute
Esophageal Adenocarcinoma
Esophageal Carcinoma
Multiple Myeloma
Esophageal cancer
Gastroesophageal Junction Adenocarcinoma
Lymphoma
Ovarian Cancer
Breast Cancer
Lung Cancer
Stomach Cancer
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Proton Therapy vs Photon Radiation
for Esophageal Cancer
This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.
Recruiting2 awards Phase 31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Barbara Ann Karmanos Cancer Institute?
Barbara Ann Karmanos Cancer Institute is a medical facility located in Detroit, Michigan. This center is recognized for care of Skin Cancer, Lymphoma, Lung Cancer, Uterine Tumors, Cancer and other specialties. Barbara Ann Karmanos Cancer Institute is involved with conducting 1,496 clinical trials across 847 conditions. There are 101 research doctors associated with this hospital, such as Ammar Sukari, Anthony F. Shields, Hirva Mamdani, MD, and Dipenkumar Modi, M.D..
Where is Barbara Ann Karmanos Cancer Institute located?
The Barbara Ann Karmanos Cancer Institute, situated in midtown Detroit, MI at 4100 John R St, is the sole National Cancer Institute (NCI)-designated comprehensive cancer center in southeast Michigan. It stands among only 54 centers of its kind across the United States.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance and Insurance Inquiries at Barbara Ann Karmanos Cancer Institute:**
- For financial assistance, contact McLaren Patient Financial Services at (844) 321-1557 or submit the Financial Assistance Application to: McLaren Corporate Services, Attn: Revenue Cycle Operations, 50820 Schoenherr Rd., Shelby Township, MI 48315.
- For insurance-related questions, call the hospital's general information line at 1-800-KARMANOS (1-800-527-6266).
What insurance does Barbara Ann Karmanos Cancer Institute accept?
The Barbara Ann Karmanos Cancer Institute accepts most health insurance plans, including Aetna, Blue Cross Blue Shield of MI, Cigna, Humana, Molina, and United Health Care among others. It is crucial to verify with your insurance provider about coverage for procedures at the Karmanos Cancer Institute before scheduling your first appointment. Patients are encouraged to review their insurance coverage annually to avoid unexpected bills.
What awards or recognition has Barbara Ann Karmanos Cancer Institute received?
The Barbara Ann Karmanos Cancer Institute, located in Detroit, Michigan, was awarded a $352,437 grant by the U CAN-CER VIVE Foundation in 2022 to support its research efforts. It has been recognized as a National Cancer Institute (NCI)-designated comprehensive cancer center since 1978, a testament to its scientific excellence and integrated research approaches in the fight against cancer.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.